The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia (BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2020-02-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | https://www.actamedindones.org/index.php/ijim/article/view/978 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839619486745886720 |
|---|---|
| author | Anastasia Putri Ikhwan Rinaldi Melva Louisa Soekamto Koesnoe |
| author_facet | Anastasia Putri Ikhwan Rinaldi Melva Louisa Soekamto Koesnoe |
| author_sort | Anastasia Putri |
| collection | DOAJ |
| description | Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia (BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the first tyrosine kinase inhibitor (TKI), which could change the prognosis of CML patients. However, there is a resistance to TKI’s, and based on transcriptomic study, increase expression of gen signal transducer and activator of transcription (STAT) 5A and runt-related transcription factor 3 (RUNX3) can cause resistance to TKI’s. The STAT5 protein, which in normal myeloid cells being activated by cytokine, in CML patients was activated even without cytokines. STAT5 refer to STAT5A and STAT5B, however they have might have different role in hematopoietic stem cells or in CML cells. This review summarizes the role of STAT5 in tyrosine kinase inhibitor resistance in CML patients. |
| format | Article |
| id | doaj-art-34b40f69dcae4373b49e3d4a25d9e76d |
| institution | Matheson Library |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2020-02-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-34b40f69dcae4373b49e3d4a25d9e76d2025-07-23T07:01:41ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322020-02-01514The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML PatientsAnastasia Putri0Ikhwan Rinaldi1Melva Louisa2Soekamto Koesnoe3Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaDivision of Haematology and Medical Oncology. Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDepartment of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta , IndonesiaDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, IndonesiaChronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia (BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the first tyrosine kinase inhibitor (TKI), which could change the prognosis of CML patients. However, there is a resistance to TKI’s, and based on transcriptomic study, increase expression of gen signal transducer and activator of transcription (STAT) 5A and runt-related transcription factor 3 (RUNX3) can cause resistance to TKI’s. The STAT5 protein, which in normal myeloid cells being activated by cytokine, in CML patients was activated even without cytokines. STAT5 refer to STAT5A and STAT5B, however they have might have different role in hematopoietic stem cells or in CML cells. This review summarizes the role of STAT5 in tyrosine kinase inhibitor resistance in CML patients.https://www.actamedindones.org/index.php/ijim/article/view/978chronic Myeloid LeukemiaSTAT5Imatinibtyrosine kinase inhibitorresistance |
| spellingShingle | Anastasia Putri Ikhwan Rinaldi Melva Louisa Soekamto Koesnoe The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients Acta Medica Indonesiana chronic Myeloid Leukemia STAT5 Imatinib tyrosine kinase inhibitor resistance |
| title | The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients |
| title_full | The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients |
| title_fullStr | The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients |
| title_full_unstemmed | The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients |
| title_short | The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients |
| title_sort | role of stat5 in tyrosine kinase inhibitor imatinib resistance in cml patients |
| topic | chronic Myeloid Leukemia STAT5 Imatinib tyrosine kinase inhibitor resistance |
| url | https://www.actamedindones.org/index.php/ijim/article/view/978 |
| work_keys_str_mv | AT anastasiaputri theroleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT ikhwanrinaldi theroleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT melvalouisa theroleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT soekamtokoesnoe theroleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT anastasiaputri roleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT ikhwanrinaldi roleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT melvalouisa roleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients AT soekamtokoesnoe roleofstat5intyrosinekinaseinhibitorimatinibresistanceincmlpatients |